{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:07:53Z","timestamp":1779944873765,"version":"3.53.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    A woman, in her mid-50s, presented with headache, confusion, and unstable gait due to a large right parietal mass subsequently diagnosed histologically as glioblastoma,\n                    <jats:italic>IDH<\/jats:italic>\n                    -wildtype, CNS WHO Grade 4 with an unmethylated\n                    <jats:italic>MGMT<\/jats:italic>\n                    promoter. Next-generation sequencing revealed a rare gene fusion involving myocyte enhancer factor 2D and neurotrophic receptor tyrosine kinase 1 (\n                    <jats:italic>MEF2D-NTRK1<\/jats:italic>\n                    ), informing our therapeutic approach. The patient was treated with temozolomide concurrently with radiotherapy, followed by tumor treating fields with adjuvant temozolomide. This report examines the distinctive molecular profile of this patient\u2019s glioblastoma, including the remarkable\n                    <jats:italic>MEF2D-NTRK1<\/jats:italic>\n                    gene fusion, and the treatment options pursued to mitigate disease progression and optimize quality of life. Here, we will discuss the potential for resistance to tyrosine kinase inhibition and the efficacy of first- and second-generation tyrosine kinase inhibitors in relation to this inhibition. Various tyrosine kinase inhibitors, including entrectinib, larotrectinib, repotrectinib, and selitrectinib, along with bevacizumab, were considered to potentially prolong progression-free survival and overall survival and improve quality of life. We expect to highlight the rarity of this case while discussing the effectiveness of second-generation tyrosine kinase inhibitors in high-grade glioblastomas with rare gene fusions. We also hope to identify the appropriate timeline and treatment sequence for post-standard care, given the lack of official guidelines regarding cases this infrequent.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1833072","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:00:39Z","timestamp":1779944439000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Anaya","family":"Dewey","sequence":"first","affiliation":[{"name":"The University of Kansas Cancer Center","place":["Kansas City, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquina C.","family":"Baranda","sequence":"additional","affiliation":[{"name":"The University of Kansas Cancer Center","place":["Kansas City, KS, United States"]},{"name":"Department of Medical Oncology, University of Kansas Medical Center","place":["Kansas City, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, University of Kansas Medical Center","place":["Kansas City, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Haeri","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, University of Kansas Medical Center","place":["Kansas City, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Milligan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Kansas Medical Center","place":["Kansas City, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"Tuncer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Kansas Medical Center","place":["Kansas City, KS, United States"]},{"name":"Department of Neurosurgery, University of Kansas Medical Center","place":["Kansas City, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with\u00a0NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01251-6","article-title":"Updates in IDH-wildtype glioblastoma","volume":"19","author":"Melhem","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030940","article-title":"Forecasting molecular features in IDH-wildtype gliomas: The state of the art of radiomics applied to neurosurgery","volume":"15","author":"Gerardi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00618","article-title":"Dual immune check point blockade in MGMT-unmethylated newly diagnosed glioblastoma: NRG Oncology BN007, a randomized phase II\/III clinical trial","volume":"43","author":"Lassman","year":"2025","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-03057-z","article-title":"Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: A subgroup analysis of the EF-14 phase III trial","volume":"141","author":"Toms","year":"2019","journal-title":"J Neuro-Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043120","article-title":"The role of MEF2 transcription factor family in neuronal survival and degeneration","volume":"24","author":"Lisek","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.694","article-title":"Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies","volume":"5","author":"Ou","year":"2024","journal-title":"MedComm (2020)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"viii713","DOI":"10.1093\/annonc\/mdy424.017","article-title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","volume":"29","author":"Demetri","year":"2018","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.3105","article-title":"Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study","volume":"42","author":"Brose","year":"2024","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01798-9","article-title":"NTRK-fused central nervous system tumours: Clinicopathological and genetic insights and response to TRK inhibitors","volume":"12","author":"Kim","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1833072\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:00:39Z","timestamp":1779944439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1833072\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":15,"alternative-id":["10.3389\/fonc.2026.1833072"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1833072","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1833072"}}